Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kerala Ayurveda's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Kerala Ayurveda's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:530163's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.39 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Kerala Ayurveda (BOM:530163) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Kerala Ayurveda 5-Year Yield-on-Cost % Related Terms
BOM:530163 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kerala Ayurveda's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kerala Ayurveda 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kerala Ayurveda's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Kerala Ayurveda's 5-Year Yield-on-Cost % falls into.
Kerala Ayurveda 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Kerala Ayurveda is calculated as
Kerala Ayurveda (BOM:530163) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kerala Ayurveda and its competitors. According to the industry distribution chart, Kerala Ayurveda ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Kerala Ayurveda's 5-Year Yield-on-Cost % too high?
Kerala Ayurveda's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Kerala Ayurveda ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kerala Ayurveda has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kerala Ayurveda's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kerala Ayurveda ranks #999999 out of 507 companies for 5-Year Yield-on-Cost %. This places Kerala Ayurveda in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kerala Ayurveda and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kerala Ayurveda's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kerala Ayurveda stock overvalued right now?
Based on GuruFocus' analysis, Kerala Ayurveda (BOM:530163) is currently considered Possible Value Trap. The stock's GF Value™ is ₹352.17, compared to a current price of ₹178.50 — trading 49.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Kerala Ayurveda's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Kerala Ayurveda (BOM:530163), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kerala Ayurveda (BOM:530163) Overvalued in 2026?
Based on GuruFocus' analysis, Kerala Ayurveda stock appears to be undervalued.
The current stock price of ₹178.50 is trading 49.3% below its estimated GF Value™ of ₹352.17.
GuruFocus considers Kerala Ayurveda to be Possible Value Trap.
Key valuation signals for BOM:530163:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹352.17 vs. price of ₹178.50 (49.3% below fair value)
No single metric tells the full story. See the BOM:530163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kerala Ayurveda Ltd is engaged in producing and selling ayurvedic products and providing healthcare services. The company offers ayurvedic medicine products for diabetes and heart health, skin and hair care, kids' health, women's care, men's care, gastro care, respiratory and allergy, general healthcare, massage oils, renal care, and joint care. It provides services through wellness clinics, resorts, hospitals, and academies. The company has only one reportable business segment, i.e., Full-spectrum Ayurvedic wellness. It generates maximum revenue from the sale of products. Geographically, the company generates maximum revenue from its business in India and also has some exposure to other markets.
48GF Score
Get the complete analysis for BOM:530163
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530163 has been successfully added to your 
